WallStreetZenWallStreetZen

NASDAQ: GTBP
Gt Biopharma Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their GTBP stock forecasts and price targets.

Forecast return on equity

Is GTBP forecast to generate an efficient return?

Company
-53.47%
Industry
124.07%
Market
-49.12%
GTBP's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is GTBP forecast to generate an efficient return on assets?

Company
-21.47%
Industry
47.18%
GTBP is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

GTBP earnings per share forecast

What is GTBP's earnings per share in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$1.74
Avg 2 year Forecast
-$0.62
Avg 3 year Forecast
-$0.52

GTBP revenue forecast

What is GTBP's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$20.1M
Avg 2 year Forecast
$59.9M
Avg 3 year Forecast
$95.9M

GTBP vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
GTBP$1.11N/AN/A
ENVB$1.22$10.00+719.67%Buy
JAGX$1.80$60.00+3,233.33%Strong Buy
TCRT$1.77N/AN/A
TOVX$0.43N/AN/A
View Top Biotech Stocks

Gt Biopharma Stock Forecast FAQ

What is GTBP's earnings growth forecast for 2025-2027?

(NASDAQ: GTBP) Gt Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.33%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.31%.

Gt Biopharma's earnings in 2025 is -$9,480,000.On average, 1 Wall Street analyst forecast GTBP's earnings for 2025 to be -$6,190,053, with the lowest GTBP earnings forecast at -$6,190,053, and the highest GTBP earnings forecast at -$6,190,053. On average, 1 Wall Street analyst forecast GTBP's earnings for 2026 to be -$2,205,651, with the lowest GTBP earnings forecast at -$2,205,651, and the highest GTBP earnings forecast at -$2,205,651.

In 2027, GTBP is forecast to generate -$1,849,901 in earnings, with the lowest earnings forecast at -$1,849,901 and the highest earnings forecast at -$1,849,901.

If you're new to stock investing, here's how to buy Gt Biopharma stock.

What is GTBP's revenue growth forecast for 2029-2031?

(NASDAQ: GTBP) Gt Biopharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 78.36%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.83%.

Gt Biopharma's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast GTBP's revenue for 2029 to be $71,399,065, with the lowest GTBP revenue forecast at $71,399,065, and the highest GTBP revenue forecast at $71,399,065. On average, 1 Wall Street analysts forecast GTBP's revenue for 2030 to be $213,023,220, with the lowest GTBP revenue forecast at $213,023,220, and the highest GTBP revenue forecast at $213,023,220.

In 2031, GTBP is forecast to generate $341,164,442 in revenue, with the lowest revenue forecast at $341,164,442 and the highest revenue forecast at $341,164,442.

What is GTBP's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: GTBP) forecast ROA is -21.47%, which is lower than the forecast US Biotechnology industry average of 47.18%.

What is GTBP's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: GTBP) Gt Biopharma's current Earnings Per Share (EPS) is -$4.07. On average, analysts forecast that GTBP's EPS will be -$1.74 for 2025, with the lowest EPS forecast at -$1.74, and the highest EPS forecast at -$1.74. On average, analysts forecast that GTBP's EPS will be -$0.62 for 2026, with the lowest EPS forecast at -$0.62, and the highest EPS forecast at -$0.62. In 2027, GTBP's EPS is forecast to hit -$0.52 (min: -$0.52, max: -$0.52).

What is GTBP's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: GTBP) forecast ROE is -53.47%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.